Together with Exact Sciences and OncXerna Therapeutics, Genialis presented a retrospective study in lung cancer patients at the 2022 SITC meeting in Boston. The study established the utility of the Xerna™ TME Panel in predicting response to immune checkpoint inhibition, and concluded that it compares favourably with existing biomarkers such as the tumor mutational burden (TMB). Adding this assay to a host of other tests in Exact Sciences’ Oncomap ExTra platform now enables researchers and clinicians to make more informed clinical decisions.

The poster is available here.

Share this story, choose your platform!